Cronocorteroid

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cronocorteroid

Property Description
Active Ingredient Betamethasone Dipropionate [INN]
Form Cream, Ointment, Gel, Lotion, or Injectable Suspension
Pharmacological Class Synthetic Glucocorticoid (Corticosteroid)
Common Purpose Suppression of inflammatory skin symptoms (e.g., pruritus, redness)
Origin Synthetic adrenocorticosteroid

Identity and Pharmacological Class

Cronocorteroid is the name for a prescription-only pharmaceutical preparation whose unique composition is defined by the active ingredient Betamethasone Dipropionate [INN]. This compound is classified as a potent synthetic corticosteroid, specifically belonging to the Glucocorticoid subclass according to pharmacological studies. Being a super-high potency agent, it is chemically engineered as an esterified derivative of prednisolone, which enhances its ability to exert targeted anti-inflammatory action at the site of application, distinguishing it from lower-potency topical steroids.

Composition, Potency, and Available Forms

The efficacy of the drug is directly tied to its strength, which is clinically classified as super-high potency. Betamethasone Dipropionate is prepared for a cutaneous route of administration in several dosage forms, most commonly as a Cream, Ointment, Gel, or Lotion. For other specific uses, it may be available as an Injectable Suspension. The product is often provided as a single-ingredient formulation to ensure the specific, powerful effect of the steroid is delivered without the influence of supplementary agents, though it may also appear in combination product formulations. This flexibility in preparation ensures the compound can be delivered effectively based on the needs of the adult or adolescent patient group.

What Is the General Purpose of This Glucocorticoid?

The general purpose of Cronocorteroid is to provide powerful, localized suppression of symptoms resulting from excessive inflammation. Its core physiological actions involve an intensive anti-inflammatory effect and a strong local immunosuppressive effect. This potent action allows the medicine to rapidly interrupt the inflammatory cycle, providing relief from the visible and irritating physical signs, such as significant redness, swelling, and severe pruritus (itching), often experienced in chronic inflammatory conditions.

What side effects are possible with Cronocorteroid?

Possible Side Effects and Safety Information

The profile of possible adverse effects for Cronocorteroid (Betamethasone Dipropionate) is based on official government regulatory classifications, identifying reactions local to the application site and systemic risks associated with potent glucocorticoid absorption.

Adverse Reactions Classified by System-Organ Class

The majority of documented adverse reactions fall under Skin and Subcutaneous Tissue Disorders. These include common local effects such as stinging, burning, pruritus (itching), irritation, folliculitis, and dryness. Effects observed over time include local changes like skin atrophy (thinning), striae (stretch marks), telangiectasia (spider veins), and hypopigmentation (skin lightening).

Systemic effects are categorized under Endocrine System Disorders, Eye Disorders, and Metabolism and Nutrition Disorders. The frequency of specific local reactions like stinging is reported as less than 1% in adult clinical trials, whereas signs of skin atrophy have been reported in up to 10% of subjects in pediatric trials.

Serious Adverse Reactions and Safety Considerations

Serious adverse reactions documented in regulatory sources are primarily related to systemic absorption. These include reversible Hypothalamic-Pituitary-Adrenal (HPA) axis suppression, which carries a risk of subsequent glucocorticosteroid insufficiency, and manifestations consistent with Cushing's syndrome. Ophthalmic risks documented include the potential for Glaucoma and Cataracts.

Risk of systemic effects is officially noted to increase with prolonged use, application over large surface areas, or use under occlusive dressings. Special population safety statements address pediatric patients, who have a greater susceptibility to systemic toxicity, including rare reports of linear growth retardation and intracranial hypertension. Cronocorteroid is formally contraindicated in individuals with a known hypersensitivity to the active ingredient or other components of the preparation.

Overdose and Emergency Response

Overdose and When to Seek Help

Cronocorteroid, a type of corticosteroid, is generally well-tolerated following acute, single-episode overdoses. However, taking a dosage significantly higher than prescribed can lead to noticeable, and sometimes serious, physiological effects, especially with large amounts or in individuals with certain pre-existing conditions.

Overdose manifestations often reflect an extreme exaggeration of the drug's known effects on multiple body systems. These can include cardiovascular changes, such as high blood pressure or irregular/rapid heart rate, and neurological symptoms, such as convulsions, confusion, agitation, or severe mood disturbances (psychosis).

Other reported symptoms in cases of acute corticosteroid exposure include nausea and vomiting, pronounced muscle weakness, and swelling in the lower extremities (ankles, feet). In individuals with pre-existing conditions like diabetes, ulcers, or heart disease, an overdose may cause a rapid and severe worsening of these conditions.

Immediate medical attention is required if a known or suspected overdose occurs, or if the individual experiences any severe or life-threatening symptoms, such as seizures, loss of consciousness, severe difficulty breathing, or severe changes in heart rhythm. Do not attempt to manage the situation at home; contact emergency services immediately.

Therapeutic Uses of Cronocorteroid

What Cronocorteroid Treats: Main Uses and Benefits

Cronocorteroid is considered relevant for managing the inflammatory and pruritic manifestations often present in corticosteroid-responsive dermatoses. This high-potency agent is commonly used in conditions involving episodic or fluctuating manifestations, notably severe cases of plaque psoriasis and certain forms of atopic dermatitis (eczema).

It is applied in addressing symptom clusters that become more disruptive during flare-ups, including pronounced symptoms such as severe redness, swelling, and persistent pruritus (itching). The anti-inflammatory support is also relevant for managing chronic changes like significant scaling, crusting, and skin thickening.

This medication generally provides support that helps ease the overall symptom burden, particularly during acute phases when symptoms interfere with daily functioning. It is often used in scenarios requiring short-term symptomatic assistance, such as for lesions on the palms or soles where greater functional stress is present.

“This medication is often used to offer symptomatic relief that helps patients cope more steadily with difficult episodes of inflammation.”

Quick Fact: Symptomatic Support for Pruritus (Itching) and Inflammatory Flare-ups

Regulatory References

  1. NIH DailyMed overview of Augmented Betamethasone Dipropionate

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Cronocorteroid — Official Regulatory Information

Cronocorteroid (Betamethasone Dipropionate) is authorized for use in Adults and Adolescents 13 years of age and older.


Eligibility Scope Restrictions and Classifications (Regulatory Basis)
Populations for whom use is allowed Adults and Adolescents 13 years and older for corticosteroid-responsive dermatoses.
Populations for whom use is not recommended Pediatric patients 12 years of age and younger due to increased risk of HPA axis suppression.
Populations for whom use is contraindicated Patients with known hypersensitivity to the ingredients or those with conditions like rosacea, perioral dermatitis, or untreated viral skin infections at the treatment site.
Pregnancy and Lactation Status Classified as Pregnancy Category C. Use during pregnancy is permitted only if the potential benefit justifies the potential risk to the fetus, and extensive or prolonged use is restricted. Caution is advised for nursing mothers.
Condition-specific eligibility rules Use requires caution in patients with Liver failure or conditions like Diabetes Mellitus, as systemic absorption may increase related risks.
Eligibility-related restrictions Regulators advise avoiding use on the face, groin, or axillae and avoiding application under occlusive dressings (e.g., tight bandages or diapers).

Official regulatory documents define who can and cannot use the medicine by strictly contraindicating it for certain skin conditions and hypersensitivity, while limiting use in at-risk populations such as young children and pregnant patients due to the high potency and potential for systemic absorption.

What should I know about interactions with other medicines?

Cronocorteroid's interaction profile is officially defined by risks related to its systemic exposure and pharmacodynamic effects, as documented by government regulatory bodies. The potential for systemic interaction is negligible under appropriate use but becomes clinically significant when absorption is enhanced.

A primary interaction risk is the pharmacodynamic interaction that occurs upon co-administration with other corticosteroid-containing products, whether systemic or topical. This combination creates an officially recognized additive risk of systemic glucocorticoid effects, specifically increasing the potential for Hypothalamic-Pituitary-Adrenal (HPA) axis suppression.

Interactions are also governed by exposure modification via administration condition. The use of occlusive dressings or application over a compromised skin barrier or large surface areas is formally restricted because it dramatically increases the rate and extent of systemic absorption, leading to higher drug exposure.

Furthermore, specific patient populations are officially noted to have an inherent risk of increased exposure. Pediatric patients are identified as having a heightened risk of systemic effects and HPA axis suppression. Similarly, patients with hepatic impairment may experience increased exposure due to potential reduced clearance of the absorbed medicine. No clinically significant drug-drug interactions involving CYP enzyme or transporter mechanisms are formally documented for the topical formulation.

Mechanism of Action

Cronocorteroid is a lipophilic molecule that diffuses across the cell membrane to primarily target the cytosolic glucocorticoid receptor (GR), functioning as an agonist. Upon binding, the activated complex translocates into the cell nucleus, where it modulates gene transcription.

This modulation occurs through two principal mechanisms: transactivation and transrepression. Via transactivation, the complex binds to glucocorticoid response elements (GREs) on the DNA, upregulating the transcription of genes encoding anti-inflammatory proteins, such as Annexin A1 (Lipocortin-1). Annexin A1 then inhibits phospholipase A2, thereby preventing the release of arachidonic acid and the subsequent synthesis of eicosanoids (prostaglandins and leukotrienes).

Simultaneously, through transrepression, the activated GR complex interferes with the activity of pro-inflammatory transcription factors, such as NF-kappa B, which downregulates the expression of numerous pro-inflammatory cytokines and chemokines. These molecular and intracellular pathways ultimately result in a systemic modification of the immune response and metabolic processes.

Dosage and Administration Information

How to use Cronocorteroid: Administration Guidelines

Cronocorteroid, which contains the potent corticosteroid Augmented Betamethasone Dipropionate, is administered in accordance with standard usage principles.

Application Route and Dosing

The medicine is formulated for topical (cutaneous) use only; it is not for use in the eyes (ophthalmic), orally, or intravaginally. The primary forms available are the Cream, Ointment, and Gel, all at a 0.05% augmented strength.

The standard regimen involves applying a thin film of the product to the affected skin areas once or twice daily. Standard guidelines emphasize a strict limitation on the total amount used: application must not exceed 50 grams per week. Therapy should be discontinued when control of the condition is achieved.


Duration and Specific Constraints

Treatment with the augmented topical formulation is generally limited to a maximum of two consecutive weeks. If no improvement is observed within this two-week period, a re-evaluation of the usage pattern is required.

Administration Constraint Labeled Instruction
Application Area Avoidance Avoid use on the face, groin, and axillae (armpits).
Occlusion Rule Do not cover the treated skin area with occlusive dressings (e.g., plastic wrap, airtight bandages).
Pediatric Use Use is not recommended in patients younger than 13 years of age.

The procedural instruction is to rub the thin film in gently and completely, and to wash hands after each application unless the hands are the site of treatment.

Recent Clinical Evidence

Research evidence / Overview of Studies for Cronocorteroid

The following summary provides an overview of the structure of the clinical research for Cronocorteroid (Betamethasone Dipropionate topical), as reported in authoritative sources. The research helps show what has been observed so far, but findings describe group patterns, not personal outcomes.


Evidence Base for Plaque Psoriasis

Research for Cronocorteroid was studied for its use in plaque psoriasis, a condition often characterized by fluctuating or episodic manifestations. The core evidence base includes controlled Randomized Controlled Trials (RCTs), systematic reviews, and meta-analyses. These trials generally focused on cohorts of Adults and Adolescents (typically 13 years and older).

Research examined objective measurements of disease severity and symptoms like pruritus (itching). Research explored short-term changes during defined observation periods, typically spanning 2 to 8 weeks. Data show patterns related to how disease severity and symptoms evolved in the observed populations. Evidence describes patterns related to symptoms linked to inflammatory or irritative states.


Evidence Base for Atopic Dermatitis (Eczema)

The evidence for Cronocorteroid in atopic dermatitis has involved controlled trials, which are relevant in trials assessing short-term symptom patterns related to this condition. The studies monitored outcomes in Adults and Adolescents (13 years and older). The studies examined outcomes related to overall disease activity (via investigator assessments) and recorded changes in the physical signs of inflammation.


Duration of Study and Long-Term Outcomes

The available research primarily focuses on short-term changes. The typical duration of the key research studies was observed in trials spanning only 2 to 8 weeks. These defined time intervals provide context for initial patterns of change.

However, long-term effects are not fully established. Evidence is limited regarding the scope of long-term observation over prolonged periods. Research exploring durability of outcomes beyond the initial short treatment phase remains insufficient.


Research Gaps and Areas of Uncertainty

Evidence quality varies across studies, and follow-up durations were limited. Sample sizes were modest in some sub-analyses, and the data for certain groups remain insufficient, especially regarding children under 13 and adults with specific comorbidities. Subgroup findings are uncertain due to the heterogeneity of the research designs, meaning study results reflect the specific conditions under which they were conducted.

Key Studies & References Augmented Betamethasone Dipropionate Cream/Ointment (Topical): Clinical Drug Monograph

Frequently Asked Questions (FAQ)

Common questions about Cronocorteroid (FAQ)


Q: What are the most common side effects reported for Cronocorteroid?

Local side effects are the most commonly reported reactions associated with the use of this topical medicine. These typically affect the application site and may include stinging, burning, itching (pruritus), irritation, and dryness. Systemic side effects, which affect the entire body, are generally uncommon when the product is used appropriately, but risks such as HPA axis suppression and symptoms consistent with Cushing's syndrome are documented in official regulatory profiles.


Q: Is it necessary to avoid alcohol completely when using Cronocorteroid?

Official product information for this topical medicine does not typically list specific interactions with alcohol or require complete avoidance. Regulatory agencies emphasize the importance of communicating all substance use, including alcohol, to a healthcare professional.


Q: Are there any known interactions between Cronocorteroid and common pain relievers?

Official documentation does not report clinically significant drug-drug interactions involving enzyme or transporter mechanisms for the topical formulation. This means that interactions with common pain relievers are not formally documented in the regulatory profile.


Q: Does Cronocorteroid affect birth control pills?

Studies suggest that estrogens, such as those found in some hormonal birth control pills, may potentially affect the way the body handles corticosteroids. Estrogens can slow down the clearance rate of the corticosteroid. The potential interaction risk indicates that close management of therapy may be necessary when these two types of medicines are used concurrently.


Q: Why do official documents sometimes mention laboratory monitoring with Cronocorteroid?

Laboratory monitoring may be mentioned in official documents because of the potential risk for systemic absorption when using potent topical corticosteroids. The potential risk of Hypothalamic-Pituitary-Adrenal (HPA) axis suppression is a documented reason why specific monitoring may be a part of the treatment approach.


Q: Can Cronocorteroid be taken with or without food?

Cronocorteroid is formulated for topical use, meaning it is applied to the skin and is not taken by mouth. Given the medicine’s non-oral route of administration, the official instructions do not link application time to food consumption.


Q: Does the time of day matter when taking Cronocorteroid?

The standard official regimen is to apply a thin film to the affected areas of skin either once or twice daily. Regulatory documentation does not specify a mandated time of day, such as morning or evening, for the application of this medication.


Q: What is the recommended period for continuous use of Cronocorteroid?

The official product labeling generally limits treatment with this augmented topical formulation to no more than two consecutive weeks. Therapy should be stopped when the skin condition is under control. Use beyond the specified duration is associated with an increased potential for systemic side effects.


Q: Does Cronocorteroid have a generic version available?

Yes, the active ingredient in Cronocorteroid, Betamethasone Dipropionate, has approved generic versions available in the market for some of its different formulations, such as the augmented ointment.


Q: Can Cronocorteroid be taken long-term?

Official product information limits the use of the augmented formulation to a maximum of two consecutive weeks. Using the medicine for a longer time is associated with an increased potential for serious systemic side effects, such as HPA axis suppression and Cushing’s syndrome.


Q: What is the difference between Cronocorteroid and a regular anti-inflammatory drug?

Cronocorteroid is classified as a potent glucocorticoid, which is a type of corticosteroid. This class of medicine works by broadly suppressing certain immune responses and severe inflammation at the cellular level. This mechanism of action is distinct from that of non-steroidal anti-inflammatory drugs (NSAIDs).


Q: Does taking Cronocorteroid affect sleep patterns?

Systemic absorption of corticosteroids can, in rare cases, lead to central nervous system effects, including changes in mood or behavior, such as trouble with sleeping. This is most commonly associated with systemic use or use beyond the recommended duration or coverage area.


Q: Will Cronocorteroid show up on a standard drug test?

The active ingredient, Betamethasone, is listed in international anti-doping classifications due to its pharmacological effects. However, regulatory labels for the topical formulation do not specifically address whether the medicine will be detected on routine, non-athletic drug screening panels.


Q: Is Cronocorteroid known to cause weight gain?

Weight gain is not listed as a common or frequent side effect of the topical formulation when it is used correctly. However, potential systemic absorption is a documented risk, and systemic effects like Cushing’s syndrome, which involve weight and fluid changes, are a rare possibility.


Q: Is Cronocorteroid suitable for people with diabetes?

The official documentation states that use requires caution in patients who have Diabetes Mellitus. This caution is advised because the systemic absorption of the corticosteroid may increase the potential for hyperglycemia, which is the medical term for high blood sugar.


Q: Is Cronocorteroid used to treat autoimmune diseases?

Cronocorteroid is formally approved for corticosteroid-responsive skin conditions such as psoriasis and eczema, which are often related to immune and inflammatory processes. Its mechanism of action involves strong immunosuppressive and anti-inflammatory effects that are key to managing such conditions.


Q: Can Cronocorteroid cause changes in mood or anxiety?

Systemic absorption of corticosteroids may rarely lead to changes in mood or mental status, which can include depression, mood swings, or increased anxiety. This potential is one reason why use is typically limited to short-term topical application to minimize systemic exposure.


Q: What should I do if a side effect of Cronocorteroid seems unusual or severe?

Regulatory guidance indicates that patients should contact their healthcare professional for medical advice regarding side effects that seem unusual, severe, or concerning. Side effects may also be reported directly to regulatory agencies, such as the FDA, via established pathways.


Q: Is Cronocorteroid approved in countries outside the US?

Yes, the active ingredient in this medicine, Betamethasone, is approved by regulatory bodies and used globally. It is officially classified as a Prescription Only Medicine in many countries, including Australia and the United Kingdom.


Q: Does Cronocorteroid affect the immune system?

Yes. As a glucocorticoid (corticosteroid), its mechanism of action involves the suppression of various immune responses within the skin. This provides a strong local anti-inflammatory and immunosuppressive effect to reduce symptoms.


Q: Are there known risks of Cronocorteroid for people with kidney problems?

Official labeling primarily emphasizes caution for patients with liver failure, but high-level regulatory resources advise that caution may also be necessary for patients with kidney disease. The presence of kidney disease may require careful assessment regarding the use of this medicine.


Q: Can I take Cronocorteroid if I am breastfeeding?

The official labeling advises caution for nursing mothers. It is not currently known if the drug is excreted into human milk after topical application. Regulatory agencies emphasize the importance of communicating with a healthcare professional regarding use while breastfeeding.


Q: Is it true that Cronocorteroid can affect bone density?

When used appropriately as a topical medicine, the risk of affecting bone density is low. However, systemic absorption, which occurs with very prolonged or extensive use, may increase the potential for developing thinning of the bones (osteoporosis).


Q: Does Cronocorteroid have different brand names in other regions?

Yes. The active ingredient in this medicine, Betamethasone Dipropionate, is a well-known compound that is marketed under numerous brand names worldwide. Examples include Diprolene, Diprosone, and Maxivate, depending on the country or region.


Q: Can people with a history of liver issues use Cronocorteroid?

The official documentation states that caution is necessary in patients with liver failure because this condition may increase the risk of side effects. The necessity of informing a healthcare professional about any history of liver issues is emphasized in patient guidance.


Q: Why is Cronocorteroid classified as a prescription-only medicine?

This medicine is classified as prescription-only because it is a potent corticosteroid. This regulatory status ensures that a qualified healthcare professional makes the proper diagnosis and determines if a strong topical medicine of this specific class is appropriate for the patient’s specific condition.


Q: Why is Cronocorteroid sometimes prescribed for conditions that aren't its main use?

Official patient information states that sometimes medicines are prescribed by a doctor for purposes other than those listed in the official leaflet. Regulatory guidance states that the medicine should only be used for the specific condition for which it was prescribed.


Q: Can Cronocorteroid cause stomach upset or digestive issues?

Gastrointestinal disturbances are not a common side effect of the topical formulation. However, stomach upset is a known potential symptom associated with systemic exposure to corticosteroids in general, which can rarely occur if the medicine is used over large areas or for long periods.


Q: What happens when Cronocorteroid is stopped suddenly?

Stopping a potent topical corticosteroid suddenly, especially after lengthy or excessive use, is associated with a risk of the skin condition flaring up, sometimes referred to as Topical Steroid Withdrawal. It also carries a risk of Hypothalamic-Pituitary-Adrenal (HPA) axis suppression, which means the body may need time to recover its natural cortisol production.


Q: How is the action of Cronocorteroid described in medical literature?

In medical and regulatory literature, the medicine is described as a Glucocorticoid that carries metabolic, immunosuppressive, and anti-inflammatory actions. It works at the cellular level by binding to specific intracellular receptors to modify the expression of genes involved in the body's inflammatory response.

How should Cronocorteroid be stored and disposed of?

The storage and disposal of Cronocorteroid (Betamethasone Dipropionate) must strictly follow the requirements defined in the official regulatory labeling. These conditions are necessary to maintain the product's stability and ensure safety.

Storage Requirement Official Regulatory Statement
Temperature Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F).
Protection Do not refrigerate or freeze the product. Keep the container tightly closed.
Child Safety Keep out of the sight and reach of children.
Disposal Dispose of unused or expired product according to local regulations.

Disposal must not be conducted via household waste or wastewater, as mandated by regulatory authorities. The product should be discarded through designated collection programs to ensure proper environmental waste management.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cronocorteroid found in:

A-Z Index: